AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+8.65%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.98B
AUM Growth
+$3.98B
(-8.1%)
Cap. Flow
-$665M
Cap. Flow
% of AUM
-16.72%
Top 10 Holdings %
Top 10 Hldgs %
92.02%
Holding
83
New
18
Increased
11
Reduced
23
Closed
3
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$12.3M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$9.21M |
| 3 |
AMAG
AMAG Pharmaceuticals, Inc.
AMAG
|
$7.35M |
| 4 |
Bank of N.T. Butterfield & Son
NTB
|
$4.95M |
| 5 |
Atara Biotherapeutics
ATRA
|
$4.81M |
Top Sells
| 1 |
BUFF
Blue Buffalo Pet Products, Inc
BUFF
|
$654M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$17.5M |
| 3 |
Citigroup
C
|
$10.6M |
| 4 |
Alibaba
BABA
|
$10.6M |
| 5 |
Aptiv
APTV
|
$8.92M |
Sector Composition
| 1 | Consumer Staples | 52.49% |
| 2 | Healthcare | 35.39% |
| 3 | Consumer Discretionary | 9.17% |
| 4 | Financials | 1.81% |
| 5 | Energy | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.35M | 0.13% |
350,000
| – | – |
|
|
XLRN
27
DELISTED
Acceleron Pharma Inc.
XLRN
| $6.33M | 0.13% |
175,000
+75,000
| +75% | +$2.71M |
|
28
Seres Therapeutics
MCRB
$162M
| $6.15M | 0.12% |
500,000
+190,000
| +61% | +$2.34M |
|
|
JUNO
29
DELISTED
Juno Therapeutics, Inc.
JUNO
| $6M | 0.12% |
200,000
| – | – |
|
|
RXDX
30
DELISTED
Ignyta, Inc.
RXDX
| $5.35M | 0.11% |
850,000
+100,000
| +13% | +$629K |
|
31
US Foods
USFD
$17.4B
| $5.31M | 0.11% |
225,000
-275,000
| -55% | -$6.49M |
|
32
Neurocrine Biosciences
NBIX
$13.5B
| $5.06M | 0.1% |
100,000
+5,000
| +5% | +$253K |
|
|
SPNC
33
DELISTED
Spectranetics Corp
SPNC
| $5.02M | 0.1% |
200,000
-150,000
| -43% | -$3.76M |
|
34
Lineage Cell Therapeutics
LCTX
$281M
| $5M | 0.1% |
1,282,050
| – | – |
|
|
35
Bank of N.T. Butterfield & Son
NTB
$1.85B
| $4.95M | 0.1% |
+200,000
| New | +$4.95M |
|
|
CEMP
36
DELISTED
Cempra, Inc.
CEMP
| $4.84M | 0.1% |
200,000
+100,000
| +100% | +$2.42M |
|
|
37
Atara Biotherapeutics
ATRA
$88.7M
| $4.81M | 0.1% |
+225,000
| New | +$4.81M |
|
38
Trip.com Group
TCOM
$46.6B
| $4.66M | 0.09% |
+100,000
| New | +$4.66M |
|
39
MacroGenics
MGNX
$121M
| $4.49M | 0.09% |
+150,000
| New | +$4.49M |
|
40
e.l.f. Beauty
ELF
$7.38B
| $4.22M | 0.08% |
+150,000
| New | +$4.22M |
|
41
Regenxbio
RGNX
$498M
| $4.2M | 0.08% |
300,000
+100,000
| +50% | +$1.4M |
|
|
CLLS
42
Cellectis
CLLS
$260M
| $3.61M | 0.07% |
150,000
-60,000
| -29% | -$1.44M |
|
43
Ultragenyx Pharmaceutical
RARE
$3.04B
| $3.55M | 0.07% |
50,000
-25,000
| -33% | -$1.77M |
|
44
Valvoline
VVV
$4.88B
| $3.52M | 0.07% |
+150,000
| New | +$3.52M |
|
|
SIOX
45
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $3.5M | 0.07% |
+250,000
| New | +$3.5M |
|
46
Intellia Therapeutics
NTLA
$1.26B
| $3.49M | 0.07% |
205,000
-20,000
| -9% | -$340K |
|
47
Ironwood Pharmaceuticals
IRWD
$201M
| $3.44M | 0.07% |
216,879
| – | – |
|
|
ONCE
48
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $3M | 0.06% |
50,000
| – | – |
|
|
AEGR
49
DELISTED
Aegerion Pharmaceuticals, Inc.
AEGR
| $2.97M | 0.06% |
1,000,000
| – | – |
|
50
Minerva Neurosciences
NERV
$16.8M
| $2.82M | 0.06% |
+200,000
| New | +$2.82M |
|